These authors concluded that the proportion of LBM relative to total body mass increased with semaglutide. Similarly, in the SURMOUNT-1 trial which studied tirzepatide, researchers found that participants treated with tirzepatide had a percent reduction in fat mass approximately 3 times greater than the reduction in lean mass, resulting in an overall improvement in body composition. More recently, a viewpoint in JAMA re-grounded the conversation: weight loss in persons with obesity primarily reduces body fat, but also decreases fat free mass (FFM)
Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes
But you can take control by being proactive
Studies conducted on mouse fibroblasts, showed that after intracellular de-esterification to TLK117, it binds to and inhibits GSTP1-1 and can disrupt the binding of GSTP1-1 to JNK
Diabetes Ther 13(5):10831096
During pregnancy, women carrying fetuses with CTD may be at increased risk to develop serious medical problems